Literature DB >> 15552275

Screening of antinuclear antibodies: comparison between enzyme immunoassay based on nuclear homogenates, purified or recombinant antigens and immunofluorescence assay.

Sergio Bernardini1, Maria Infantino, Lorenza Bellincampi, Marzia Nuccetelli, Antonella Afeltra, Roberta Lori, Antonino Biroccio, Andrea Urbani, Giorgio Federici.   

Abstract

Current clinical practice considers antinuclear antibody (ANA) testing as a screening test; this has a major impact on laboratory work with a growing volume of analyses that need to be performed rapidly, to maintain good specificity and sensitivity. Ongoing discussions have been raised in order to identify the best technology to use in ANA screening, taking into account both clinical and economical implications. The aim of our study was to compare three different enzyme immunoassays (EIA) with immunofluorescence (IF) assay in order to identify which test is better for use as a screening test. The study was performed on 473 sera and the three different EIA tests were based on nuclear homogenates from HeLa cells, purified antigens from HEp-2 cells and recombinant antigens, respectively. The concordance between EIA-ANA and IF-ANA techniques, determined by the K statistic, was acceptable, but not complete, and discrepancies between both EIA-positive/IF-negative samples and IF-positive/EIA-negative were found. Both methods show interesting diagnostic abilities, however, the IF-ANA assay seems to be the first choice test in a well-standardized immunofluorescence laboratory with experienced microscopists, whereas the EIA test might be useful especially in large-scale ANA screening.

Mesh:

Substances:

Year:  2004        PMID: 15552275     DOI: 10.1515/CCLM.2004.235

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  8 in total

1.  The burden of the variability introduced by the HEp-2 assay kit and the CAD system in ANA indirect immunofluorescence test.

Authors:  M Infantino; F Meacci; V Grossi; M Manfredi; M Benucci; M Merone; P Soda
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Clinical value of multiplexed bead-based immunoassays for detection of autoantibodies to nuclear antigens.

Authors:  Erik Avaniss-Aghajani; Sophia Berzon; Arlen Sarkissian
Journal:  Clin Vaccine Immunol       Date:  2007-03-21

3.  Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus.

Authors:  Gabriela Schmajuk; Bimba F Hoyer; Martin Aringer; Sindhu R Johnson; David I Daikh; Thomas Dörner
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-09-11       Impact factor: 4.794

4.  Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity.

Authors:  Ehud Paz; Muhammed Adawi; Idit Lavi; Yehuda Mussel; Reuven Mader
Journal:  Rheumatol Int       Date:  2007-02-16       Impact factor: 2.631

5.  Automation in indirect immunofluorescence testing: a new step in the evolution of the autoimmunology laboratory.

Authors:  Renato Tozzoli; Antonio Antico; Brunetta Porcelli; Danila Bassetti
Journal:  Auto Immun Highlights       Date:  2012-07-13

Review 6.  Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.

Authors:  Michael Mahler; Pier-Luigi Meroni; Xavier Bossuyt; Marvin J Fritzler
Journal:  J Immunol Res       Date:  2014-04-27       Impact factor: 4.818

7.  Evaluation of an automated connective tissue disease screening assay in Korean patients with systemic rheumatic diseases.

Authors:  Seri Jeong; Heeyoung Yang; Hyunyong Hwang
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

8.  The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA.

Authors:  Nancy A Stearns; Shuxia Zhou; Michelle Petri; Steven R Binder; David S Pisetsky
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.